These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 35876710)

  • 21. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.
    Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP
    Lancet Glob Health; 2021 May; 9(5):e620-e627. PubMed ID: 33770513
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the
    Jeffrey JL; St Clair M; Wang P; Wang C; Li Z; Beloor J; Talarico C; Fridell R; Krystal M; White CT; Griffith S; D'Amico R; Smith K; Van Eygen V; Vingerhoets J; Vandermeulen K; Spreen W; van Lunzen J
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0170221. PubMed ID: 34978890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.
    Orkin C; Bernal Morell E; Tan DHS; Katner H; Stellbrink HJ; Belonosova E; DeMoor R; Griffith S; Thiagarajah S; Van Solingen-Ristea R; Ford SL; Crauwels H; Patel P; Cutrell A; Smith KY; Vandermeulen K; Birmingham E; St Clair M; Spreen WR; D'Amico R
    Lancet HIV; 2021 Nov; 8(11):e668-e678. PubMed ID: 34656207
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The propensity for long-acting cabotegravir and rilpivirine every 2 months among HIV-infected people eligible for treatment.
    Alberton F; Nozza S; Raccagni AR; Galli L; Spagnuolo V; Bossolasco S; Cernuschi M; Canetti D; Hasson H; Castagna A; Gianotti N
    J Med Virol; 2023 Jan; 95(1):e28330. PubMed ID: 36415058
    [No Abstract]   [Full Text] [Related]  

  • 25. Compassionate use of long-acting cabotegravir plus rilpivirine for people living with HIV-1 in need of parenteral antiretroviral therapy.
    D'Amico R; Cenoz Gomis S; Moodley R; Van Solingen-Ristea R; Baugh B; Van Landuyt E; Van Eygen V; Min S; Cutrell A; Foster C; Chilton D; Allard SD; Ruiter A
    HIV Med; 2023 Feb; 24(2):202-211. PubMed ID: 35945163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human Immunodeficiency Virus Type 1 RNA Levels in Rectal and Seminal Compartments After Switching to Long-Acting Cabotegravir Plus Rilpivirine: A Longitudinal Study.
    Masiá M; Fernández-González M; Agulló V; Mascarell P; Padilla S; García-Abellán J; Gutiérrez F
    Clin Infect Dis; 2023 Feb; 76(3):e748-e751. PubMed ID: 35986671
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transient Viremia in Young Adults With HIV After the Switch to Long-Acting Cabotegravir and Rilpivirine: Considerations for Dosing Schedule and Monitoring.
    Rakhmanina N; Richards K; Adeline Koay WL
    J Acquir Immune Defic Syndr; 2023 Mar; 92(3):e14-e17. PubMed ID: 36480701
    [No Abstract]   [Full Text] [Related]  

  • 28. Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infection.
    Chounta V; Snedecor SJ; Wu S; Van de Velde N
    BMC Infect Dis; 2022 May; 22(1):428. PubMed ID: 35508986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks.
    Murray M; Antela A; Mills A; Huang J; Jäger H; Bernal E; Lombaard J; Katner H; Walmsley S; Khuong-Josses MA; Hudson K; Dorey D; Griffith S; Spreen W; Vanveggel S; Shaefer M; Margolis D; Chounta V
    AIDS Behav; 2020 Dec; 24(12):3533-3544. PubMed ID: 32447500
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV.
    Courlet P; Alves Saldanha S; Cavassini M; Marzolini C; Choong E; Csajka C; Günthard HF; André P; Buclin T; Desfontaine V; Decosterd LA
    J Mass Spectrom; 2020 Jun; 55(6):e4506. PubMed ID: 32160389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV.
    Bares SH; Scarsi KK
    Curr Opin HIV AIDS; 2022 Jan; 17(1):22-31. PubMed ID: 34871188
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV drug resistance monitoring in the era of dolutegravir and injectable long-acting cabotegravir in resource-limited settings.
    Washaya T; Manasa J; Kouamou V
    AIDS; 2023 Aug; 37(10):1629-1631. PubMed ID: 37450629
    [No Abstract]   [Full Text] [Related]  

  • 33. The future of long-acting cabotegravir plus rilpivirine therapy: deeds and misconceptions.
    Rusconi S; Santoro MM; Capetti AF; Gianotti N; Zazzi M
    Int J Antimicrob Agents; 2022 Sep; 60(3):106627. PubMed ID: 35760225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
    Jaeger H; Overton ET; Richmond G; Rizzardini G; Andrade-Villanueva JF; Mngqibisa R; Hermida AO; Thalme A; Belonosova E; Ajana F; Benn PD; Wang Y; Hudson KJ; Español CM; Ford SL; Crauwels H; Margolis DA; Talarico CL; Smith KY; van Eygen V; Van Solingen-Ristea R; Vanveggel S; Spreen WR
    Lancet HIV; 2021 Nov; 8(11):e679-e689. PubMed ID: 34648734
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
    Margolis DA; Brinson CC; Smith GHR; de Vente J; Hagins DP; Eron JJ; Griffith SK; Clair MHS; Stevens MC; Williams PE; Ford SL; Stancil BS; Bomar MM; Hudson KJ; Smith KY; Spreen WR;
    Lancet Infect Dis; 2015 Oct; 15(10):1145-1155. PubMed ID: 26201299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The optimum implementation of long-acting injectable cabotegravir-rilpivirine in sub-Saharan Africa.
    Dawood H
    Lancet Glob Health; 2021 May; 9(5):e563-e564. PubMed ID: 33770512
    [No Abstract]   [Full Text] [Related]  

  • 37. Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy.
    Mills A; Richmond GJ; Newman C; Osiyemi O; Cade J; Brinson C; De Vente J; Margolis DA; Sutton KC; Wilches V; Hatch S; Roberts J; McCoig C; Garris C; Vandermeulen K; Spreen WR
    AIDS; 2022 Feb; 36(2):195-203. PubMed ID: 34652287
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults.
    Letendre SL; Mills A; Hagins D; Swindells S; Felizarta F; Devente J; Bettacchi C; Lou Y; Ford S; Sutton K; Shaik JS; Crauwels H; D'Amico R; Patel P
    J Antimicrob Chemother; 2020 Mar; 75(3):648-655. PubMed ID: 31873746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cabotegravir/rilpivirine (Cabenuva) for HIV-1 infection.
    Med Lett Drugs Ther; 2021 May; 63(1625):81-83. PubMed ID: 34180282
    [No Abstract]   [Full Text] [Related]  

  • 40. Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment.
    Swindells S; Lutz T; Van Zyl L; Porteiro N; Stoll M; Mitha E; Shon A; Benn P; Huang JO; Harrington CM; Hove K; Ford SL; Talarico CL; Chounta V; Crauwels H; Van Solingen-Ristea R; Vanveggel S; Margolis DA; Smith KY; Vandermeulen K; Spreen WR
    AIDS; 2022 Feb; 36(2):185-194. PubMed ID: 34261093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.